ABVX

Abivax SA

ABVX.PA abivax.com + Research + Basket
ISIN FR0012333284
Employees 98
Phone 33 1 53 83 09 63
Fiscal year end December
Address 7-11 Boulevard Haussmann, Paris, France, 75009
79.05
+0.00 (+0.00%)
EUR · PA
52-week range
60.45
139.00
Trading at 24% of the 52-week range
Market Cap
6.85B
P/E Ratio
0.00
Forward P/E
1.00
Book Value
4.59
Div. Yield
N/A
% Institutions
52.23%
% Insiders
3.96%

1 Year

-12.7%

3 Year

+792.2%

10 Year

+1,013.4%
Description

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Actions

Add an action for ABVX.PA, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Marc M. P. de Garidel M.B.A. CEO & Director 1958
Mr. Didier Blondel EVP, CFO & Board Secretary 1964
Mr. Timothy P. Kelly M.B.A. Chief Technical Officer 1969
Mr. Patrick Malloy Senior VP & Head of Investor Relations NA
Ms. Ida Hatoum Chief People & Compliance Officer 1975
Mr. James Berger Global Head of Marketing NA
Mr. Pierre Courteille M.B.A. Chief Business Officer 1969

Financial Highlights

▼
Market Cap: $6.85B
EBITDA: $-291.55M
Book Value: $4.59
Earnings/Share: $-5.21
Profit Margin: 0.00%
Operating Margin: -8,617.93%
ROA (TTM): -62.88%
ROE (TTM): -252.35%
Revenue (TTM): $4.67M
Revenue/Share (TTM): $0.06
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -6.80%

Valuation Metrics

Enterprise Value: $6.69B
Trailing P/E: 0.00
Forward P/E: 1.00

Shares Statistics

Shares Outstanding: 87.54M
Shares Float: 65.02M
% Insiders: 3.96%
% Institutions: 52.23%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-1.07M
Gross Profit
subtotal
$-1.07M
SG&A
adjust
$-72.64M
R&D
adjust
$-177.76M
Operating Income
subtotal
$-250.63M
Other / Non-Operating Items
adjust
$-85.48M
Net Income
subtotal
$-336.10M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ABVX.PA!